| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.0M | — | -9.5% |
| R&D Expense | $80.7M | — | -25.5% |
| SG&A Expense | $34.8M | — | +20.1% |
| Operating Income | -$100.5M | — | +16.8% |
| Net Income | -$96.2M | — | +15.8% |
| EPS (Basic) | -$0.81 | — | +26.4% |
| EPS (Diluted) | -$0.81 | — | +26.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $134.7M | -13.4% | +6.2% |
| Short-term Investments | $241.3M | -18.0% | -36.0% |
| Accounts Receivable | $9.1M | -3.6% | -13.1% |
| Current Assets | $466.4M | -11.6% | -15.4% |
| Total Assets | $758.8M | -9.9% | -23.1% |
| Current Liabilities | $76.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$117.3M | — | +21.2% |
| Capital Expenditures | $79K | — | -89.3% |
| Investing Cash Flow | $66.3M | — | -29.7% |
| Financing Cash Flow | $33.6M | — | — |
| Free Cash Flow | -$117.4M | — | +21.5% |
| -32.1% |
| Total Liabilities | $137.8M | -19.3% | -33.2% |
| Stockholders' Equity | $620.9M | -7.5% | -20.4% |